MedPath

Atrial Fibrillation Progression Trial

Phase 1
Conditions
Atrial Fibrillation
MedDRA version: 20.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disorders
Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Registration Number
EUCTR2012-002338-35-AT
Lead Sponsor
Biosense Webster, Inc.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
330
Inclusion Criteria

• Patients with recurrent AF for 2 years, with = 2 episodes over the last 6 months; 1 episode within the last 1 year (12 months) must be documented by electrocardiogram (ECG), TTM, HM, or telemetry strip.
• HATCH Score of at least =1 and = 4.
• Eligible for catheter ablation and for anti-arrhythmic or rate control medications, after having failed no more than 2 prescribed drugs (either anti-arrhythmic or rate control drug).
• Age 60 years or older.
• LA diameter = 55mm by TTE.
• LV ejection fraction = 50% when in sinus rhythm or LV ejection fraction = 35% when in AF.
• Signed Patient Informed Consent Form.
• Able and willing to comply with protocol requirements, including all baseline and followup testing
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 50
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 280

Exclusion Criteria

• Patients awaiting cardiac transplantation or other cardiac surgery.
• Acute illness (ongoing) or active systemic infection or sepsis.
• Reversible causes of AF, including thyroid disorders, acute alcohol intoxication, recent major surgical procedures or trauma.
• Recent cardiac events including MI, PCI, or valve or bypass surgery in the preceding 3 months.
• Heart failure decompensation.
• Previous stroke.
• Pulmonary embolism or recent atrial embolism/thrombosis.
• Hypertrophic obstructive cardiomyopathy.
• Class IV angina or Class IV CHF (including past or planned heart transplantation).
• Mandated anti-arrhythmic drug therapy for disease conditions other than AF.
• Heritable arrhythmias or increased risk for torsade de pointes with class I or III Drugs.
• Prior LA catheter ablation with the intention of treating AF; prior surgical interventions for AF such as the MAZE procedure.
• Prior AV nodal ablation.
• Patients presenting contra-indications for the study catheter(s), as indicated in the respective Instructions For Use.
• Contraindication to warfarin, other anticoagulation therapy, or all anti-platelet medications.
• Medical conditions limiting expected survival to < 3 years.
• Concurrent participation in any other clinical study.
• Prior history of non-adherence to prescribed drug regimens.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath